|
08 Mar 2007 |
ZymoGenetics Provides Update on rhThrombin Development Plans
|
|
08 Mar 2007 |
Allon product AL-108 successful in Phase Ib clinical trial
|
|
07 Mar 2007 |
Clinquest Group and TNO sign licensing agreement on protein for inflammatory disorders
|
|
07 Mar 2007 |
AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
|
|
07 Mar 2007 |
Nautilus Biotech and HanAll Pharmaceutical announce license agreement to develop three Nautilus Biotech products in South Korea
|
|
06 Mar 2007 |
Cytheris Releases Promising Clinical Data on its Interleukin-7 Immune Enhancer at the 2007 CROI Meeting in Los Angeles
|
|
06 Mar 2007 |
Transition Therapeutics Announces Positive Data from E1-I.N.T.(TM) Clinical Trials in Type 1 and Type 2 Diabetes Patients
|
|
06 Mar 2007 |
InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis
|
|
03 Mar 2007 |
GTC Biotherapeutics Enters Into Process Development And Clinical Supply Manufacturing Services Agreement With Pharmathene For Protexia
|
|
02 Mar 2007 |
Biolex Therapeutics Researchers Present Preclinical Data for Direct-Acting Thrombolytic BLX-155 at Scientific Conference
|
|
02 Mar 2007 |
Levemir(R) approved in Europe for use in combination with oral antidiabetic drugs
|
|
02 Mar 2007 |
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
|
|
02 Mar 2007 |
Kamada begins phase III clinical trial in the U.S. with its Alpha-1 Antitrypsin product indicated for Congenital Emphysema
|
|
28 Feb 2007 |
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
|
|
28 Feb 2007 |
Nautilus Biotech announces IND filing for Belerofon, its oral, long-lasting, Interferon-alpha drug
|
|
28 Feb 2007 |
Jerini Plans to Submit US New Drug Application in Third Quarter 2007 for Icatibant in Hereditary Angioedema
|
|
28 Feb 2007 |
Human Genome Sciences Announces Positive Interim Results Of Phase 2B Trial Of Albuferon(R) With Ribavirin In Treatment-Naïve Patients With Chronic Hepatitis C
|
|
28 Feb 2007 |
Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) With Ribavirin In Treatment-Naïve Patients With Chronic Hepatitis C Genotypes 2 And 3
|
|
27 Feb 2007 |
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
|
|
27 Feb 2007 |
Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the brain, but does not improve long-term clinical outcomes
|
|
27 Feb 2007 |
Lilly Plans New Clinical Trial of Xigris
|
|
27 Feb 2007 |
Ipsen Grants Galderma Exclusive Rights to Develop, Promote and Distribute Its Botulinum Toxin Type A Product for Aesthetic Indications in Europe and Certain Other Territories
|
|
26 Feb 2007 |
TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
|
|
24 Feb 2007 |
Recruitment temporarily suspended into C.E.R.A. Phase II oncology trial
|
|
22 Feb 2007 |
Breakthrough oral delivery for arthritis sufferers
|
